Stapley Marc A.'s Insider Trades & SAST Disclosures
Stapley Marc A.'s most recent trade in Veracyte Inc was a trade of 90,601 Common Stock done . Disclosure was reported to the exchange on March 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Stapley Marc A..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 90,601 | 358,636 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.82 per share. | 04 Mar 2025 | 28,189 | 292,543 (0%) | 0% | 32.8 | 925,248 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.91 per share. | 04 Mar 2025 | 23,414 | 269,129 (0%) | 0% | 33.9 | 794,009 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.37 per share. | 04 Mar 2025 | 1,094 | 268,035 (0%) | 0% | 34.4 | 37,599 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 67,277 | 375,329 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 34,273 | 341,056 (0%) | 0% | 33.8 | 1,159,798 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 20,324 | 320,732 (0%) | 0% | 34.8 | 706,462 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.37 per share. | 13 Dec 2024 | 5,190 | 307,745 (0%) | 0% | 43.4 | 225,080 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.14 per share. | 13 Dec 2024 | 400 | 307,345 (0%) | 0% | 44.1 | 17,657 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 5,748 | 312,935 (0%) | 0% | 44.1 | 253,602 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 5,748 | 318,683 (0%) | 0% | 31.5 | 181,349 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 15 Aug 2024 | 6,250 | 40,326 (0%) | 0% | 32 | 200,000 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 6,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 126.27 per share. | 15 Aug 2024 | 3,959 | 34,657 (0%) | 0% | 126.3 | 499,903 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 125.28 per share. | 15 Aug 2024 | 1,110 | 38,616 (0%) | 0% | 125.3 | 139,061 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 123.98 per share. | 15 Aug 2024 | 600 | 39,726 (0%) | 0% | 124.0 | 74,388 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 126.91 per share. | 15 Aug 2024 | 581 | 34,076 (0%) | 0% | 126.9 | 73,735 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 5,746 | 323,994 (0%) | 0% | 20.8 | 119,230 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 1,716 | 34,076 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 1,246 | 1,246 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corporation | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 15 May 2024 | 6,250 | 38,610 (0%) | 0% | 32 | 200,000 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 6,250 | 6,250 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 112.91 per share. | 15 May 2024 | 2,200 | 34,360 (0%) | 0% | 112.9 | 248,402 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 111.82 per share. | 15 May 2024 | 2,050 | 36,560 (0%) | 0% | 111.8 | 229,231 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 113.68 per share. | 15 May 2024 | 2,000 | 32,360 (0%) | 0% | 113.7 | 227,360 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,780 | 335,711 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.10 per share. | 15 Mar 2024 | 5,971 | 329,740 (0%) | 0% | 21.1 | 125,988 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 114,724 | 323,931 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 13,286 | 209,207 (0%) | 0% | 24 | 318,864 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 6,250 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corporation | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 29 Feb 2024 | 6,250 | 38,610 (0%) | 0% | 32 | 200,000 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 88.76 per share. | 29 Feb 2024 | 2,437 | 36,173 (0%) | 0% | 88.8 | 216,308 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 91.21 per share. | 29 Feb 2024 | 2,313 | 32,360 (0%) | 0% | 91.2 | 210,969 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 90.54 per share. | 29 Feb 2024 | 1,500 | 34,673 (0%) | 0% | 90.5 | 135,810 | Common Stock |
| Glaukos Corporation | Stapley Marc A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,082 | 32,398 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,044 | 32,360 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Marc Stapley A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corporation | Marc Stapley A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.28 per share. | 14 Dec 2023 | 10,000 | 41,316 (0%) | 0% | 7.3 | 72,750 | Common Stock |
| Glaukos Corporation | A. Stapley Marc | Director | Sale of securities on an exchange or to another person at price $ 75.61 per share. | 14 Dec 2023 | 9,206 | 38,360 (0%) | 0% | 75.6 | 696,066 | Common Stock |
| Glaukos Corporation | Marc Stapley A. | Director | Sale of securities on an exchange or to another person at price $ 76.35 per share. | 14 Dec 2023 | 7,044 | 31,316 (0%) | 0% | 76.3 | 537,809 | Common Stock |
| Glaukos Corporation | Stapley Marc A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 6,250 | 18,750 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corporation | A. Stapley Marc | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 14 Dec 2023 | 6,250 | 47,566 (0%) | 0% | 32 | 200,000 | Common Stock |
| Veracyte Inc | A. Stapley Marc | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 3,203 | 221,882 (0%) | 0% | 26.5 | 85,008 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 3,203 | 227,696 (0%) | 0% | 26.7 | 85,584 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 3,230 | 31,316 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 128,869 | 128,869 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 78,044 | 230,899 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 6,029 | 152,855 (0%) | 0% | 24.1 | 145,299 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,900 | 28,086 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.14 per share. | 02 Dec 2022 | 1,012 | 158,299 (0%) | 0% | 29.1 | 29,490 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 02 Sep 2022 | 1,012 | 159,311 (0%) | 0% | 19.2 | 19,410 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 16.33 per share. | 10 Jun 2022 | 60,000 | 159,761 (0%) | 0% | 16.3 | 980,094 | Common Stock |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,364 | 26,186 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 02 Jun 2022 | 4,047 | 99,761 (0%) | 0% | 18.2 | 73,777 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 103,026 | 103,026 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 56,537 | 103,808 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 1,758 | 21,822 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 2,382 | 20,064 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 138,051 | 138,051 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Marc A. Stapley | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 46,807 | 46,807 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 1,184 | 17,682 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 3,900 | 16,498 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges